Verastem/$VSTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
$VSTM
Sector
Primary listing
Employees
78
Headquarters
Website
Verastem Metrics
BasicAdvanced
$489M
-
-$3.52
0.83
-
Price and volume
Market cap
$489M
Beta
0.83
52-week high
$11.25
52-week low
$3.17
Average daily volume
2M
Financial strength
Current ratio
3.46
Quick ratio
3.308
Long term debt to equity
223.366
Total debt to equity
234.954
Interest coverage (TTM)
-58.03%
Profitability
EBITDA (TTM)
-156.407
Gross margin (TTM)
85.12%
Net profit margin (TTM)
-7,793.87%
Operating margin (TTM)
-7,326.11%
Effective tax rate (TTM)
-0.11%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-64.80%
Return on equity (TTM)
-437.92%
Valuation
Price to revenue (TTM)
194.886
Price to book
13.57
Price to tangible book (TTM)
23.95
Price to free cash flow (TTM)
-3.464
Free cash flow yield (TTM)
-28.87%
Free cash flow per share (TTM)
-2.295
Growth
Revenue change (TTM)
-78.63%
Earnings per share change (TTM)
5.62%
3-year revenue growth (CAGR)
-12.07%
3-year earnings per share growth (CAGR)
-12.01%
10-year earnings per share growth (CAGR)
-17.03%
What the Analysts think about Verastem
Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Bulls say / Bears say
The U.S. FDA granted accelerated approval for AVMAPKI™ FAKZYNJA™ as the first-ever treatment for KRAS-mutated recurrent low-grade serous ovarian cancer, establishing a new therapy for this rare disease.
AVMAPKI FAKZYNJA CO-PACK recorded $2.1 million in net product revenue in its first six weeks, showing strong early sales momentum.
Verastem finished Q2 2025 with $164.3 million in cash and cash equivalents, providing enough funding to support operations into the second half of 2026 and flexibility to advance trials.
Verastem reported a net loss of $25.93 million in Q2, mainly due to higher R&D and administrative spending, which delays profitability.
Operating expenses totaled $45.90 million in Q2, far outpacing net product revenue of $2.1 million, showing a significant burn rate during commercial launch.
With $164.3 million in cash only covering operations until the second half of 2026, Verastem may need additional funding or could face dilution risk if future trial results or revenue don't meet expectations.
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
Verastem Financial Performance
Revenues and expenses
Verastem Earnings Performance
Company profitability
Verastem News
AllArticlesVideos
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
Business Wire5 days ago
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
Business Wire1 week ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verastem stock?
Verastem (VSTM) has a market cap of $489M as of October 27, 2025.
What is the P/E ratio for Verastem stock?
The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of October 27, 2025.
Does Verastem stock pay dividends?
No, Verastem (VSTM) stock does not pay dividends to its shareholders as of October 27, 2025.
When is the next Verastem dividend payment date?
Verastem (VSTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Verastem?
Verastem (VSTM) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.